Brian Reed: Hey — good to be here. You've been looking at this Mayo Clinic thing all morning, yeah?
Eliza Ward: Most of the morning, actually. Seven studies, all dropping together — that's the thing that caught me.
Brian Reed: Seven. At once.
Eliza Ward: Coordinated cluster, yeah. Marissa Schafer's lab at Mayo is behind several of them — all centered on senescent cells. The ones that stop dividing but don't die.
Brian Reed: And that's the — okay, so I want to make sure I have this right before we go anywhere. A senescent cell just... stops. It stops dividing. But it's still there, still running.
Eliza Ward: Think of it like a factory that shuts down production entirely — no more goods going out — but leaves all the machinery on. Running. And leaking. That leakage is what they call the SASP — inflammatory signals spilling into the tissue around it, damaging everything nearby.
Brian Reed: And the core finding from this cluster is that — wait, it's not one kind of factory, right? That's the twist.
Eliza Ward: That's it exactly. Senescent cell heterogeneity — different machines, different exhaust, different neighborhoods getting damaged. Which immediately breaks every drug pitch that treats them like a single target.
Brian Reed: And that's where the IL-23R thing cuts through for me — because that's not a mouse. That's 80 actual people.
Eliza Ward: That's the line. Forty men, forty women, aged 20 to 90 — blood draws, not a mouse liver. Marissa Schafer's group at Mayo measured IL-23R rising across that entire age range, and it concentrated in kidney tissue specifically.
Brian Reed: So that's the first human-validated signal in this whole cluster.
Eliza Ward: First one linked specifically to cellular senescence, yeah. And — wait, the mechanism piece matters here — senescent cells aren't just passively expressing IL-23R. They're releasing soluble IL-23R into surrounding tissue. Actively. That's not just a marker, that's the cells announcing themselves.
Brian Reed: But hang on — is it driving anything? Or is it just showing up at the scene?
Eliza Ward: That's — no, that's the honest answer from Mayo's own reporting. Causal direction is unresolved. They say so explicitly. IL-23R rises with age, yes. It correlates with senescence markers. But whether elevated IL-23R is actually accelerating aging or just tracking it — that's not established yet.
Brian Reed: So the headline probably outruns it a little.
Eliza Ward: Useful biomarker candidate, not a therapeutic target — that's the honest version. I mean, think about what that actually means clinically. Say it's 2027. A 68-year-old woman, mild cognitive slowing, routine blood panel. Her physician sees IL-23R elevated. Right now there's no action attached to that number. Senolytics and senomorphics did reduce circulating IL-23R in animal models — but that's still mice.
Brian Reed: So the signal exists in humans. The response to it exists in mice. And nobody's closed that gap yet.
Eliza Ward: And that gap is exactly what some of the coverage is skipping over — because tomatidine is the complicated part.
Brian Reed: The compound from the pre-clinical work. Yeah. That's the one I keep seeing framed like it's almost ready.
Eliza Ward: It isn't. That's — no, let me be direct about this. Every tomatidine result is mouse data. Old mice, yes — showing reduced inflammatory measures, improved physical frailty scores, better performance on cognitive tasks. But that is a mouse liver. Not a human kidney.
Brian Reed: So what would it actually take to call it more than pre-clinical?
Eliza Ward: Human trials. Which don't exist yet. And — wait, this is the part I keep wanting to push on — is Schafer's group even claiming otherwise? Because I went back to their actual framing and it's 'necessary groundwork to develop new therapies.' That's foundation language. That's careful.
Brian Reed: Right, so the overclaim isn't coming from Mayo. It's the translation from lab release to headline that drops the caveat.
Eliza Ward: Which matters, because the INK-ATTAC model is genuinely striking — drug-inducible removal of p16-expressing cells, actual delay of age-related pathology — and that result earns the attention. But p16, encoded by CDKN2A, is a mouse senescence marker showing up in a mouse model. Sixty-plus years after Hayflick's 1961 limit and we still haven't closed the loop to a human drug.
Brian Reed: Hang on — sixty years is the part people miss. Hayflick names the thing in 1961, and we're still calling the treatment outcomes pre-clinical.
Eliza Ward: And there's a reason for that — one we haven't touched yet — that actually makes the whole senolytic and senomorphic pipeline more complicated than the timeline alone suggests. We'll get there.
Brian Reed: The reason being — and I think this is actually the thing — senescent cells aren't just passengers we should've cleared out sooner. They're doing something. Early on, I mean. Tumor suppression. Wound healing. These cells stop dividing specifically to prevent cancer.
Eliza Ward: Hayflick's whole insight — 1961 — was about tumor suppression. That's why cells hit the limit. To stop runaway replication.
Brian Reed: So the same cellular state that is protecting a 35-year-old from pancreatic cancer is — wait, forty years later — it's the thing inflaming their kidney?
Eliza Ward: That's the trade. Exactly that. The same mechanism — and nobody in Schafer's cluster is claiming they've resolved it. They acknowledge it explicitly. The cell that protected you becomes the SASP source that drives inflammageing — cardiovascular disease, neurodegeneration — at 75.
Brian Reed: So a broad senolytic — something that just clears p16-expressing cells wholesale — you could theoretically be swapping chronic inflammation for elevated cancer risk or impaired wound healing.
Eliza Ward: That's — yeah, that's not a theoretical concern. That's why senescent cell heterogeneity isn't just a scientific curiosity. It's a clinical imperative. Which cells, which tissue, which life stage. You have to know all three before you touch anything. And right now — I mean, we don't have a biopsy protocol that tells a clinician that.
Brian Reed: Which means the whole senolytics versus senomorphics debate — kill them or quiet them — actually hinges on a targeting problem nobody's solved.
Eliza Ward: Right — and the concrete signal to watch is whether any follow-on work from Schafer's group produces a tissue-specific subtype map. That's the thing that unlocks a clinical decision. Not another mouse frailty score.
Brian Reed: Because until you have that map, a physician looking at elevated IL-23R on a blood panel can see the signal. They just can't do anything safe with it.
Eliza Ward: And that's actually — I mean, that's where I land on all of this. IL-23R is the first human-blood signal specifically tied to cellular senescence. That's real. Eighty people, Marissa Schafer's lab, the correlation is there. But whether it's a driver or a passenger — that's the next result to watch for. Not tomatidine's Phase One. Not another mouse frailty score. Causal validation of IL-23R in human trials. That's the line.
Brian Reed: And the field's question is not 'can we clear senescent cells.' That's answerable in a mouse. The INK-ATTAC model answered it in a mouse. The question is which cells, in which person, at which point in their life. And whether eliminating them at 68 trades inflammageing for something worse.
Eliza Ward: That trade is genuinely unresolved. Nobody in this cluster is claiming otherwise.
Brian Reed: So we're sitting with — let me just say this plainly — a biomarker that correlates, a mechanism that's real, and a targeting problem that nobody has solved. That's where the science actually is right now.
